Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol for Sporadic Inclusion Body Myositis
NCT00769860Phase 3Completed
- Start
- Sep 2008
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of arimoclomol in inclusion body myositis (IBM). Started Sep 2008; status: completed.
02
Drugs
arimoclomol
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT00769860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00769860.